David
Jiménez Castro
Profesor/a Titular Universidad
Academic Medical Center
Ámsterdam, HolandaAcademic Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (5)
2023
-
Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study
Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2929-2940
2020
-
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries
European Journal of Internal Medicine, Vol. 82, pp. 48-55
-
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months
Thrombosis Research, Vol. 196, pp. 297-304
2018
-
Correction: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [Thrombosis Journal, 16, (2018) (9)] DOI: 10.1186/s12959-018-0163-7
Thrombosis Journal
-
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
Thrombosis Journal, Vol. 16, Núm. 1